A Study Assessing Romiplostim to Treat Low Platelet Counts after Chemotherapy and Autologous Stem Cell Transplantation in People with Blood Cancers

Share
Print

Full Title

An Open-Label, Pilot Study of Romiplostim for Conditioning Regimen-Related Thrombocytopenia after High-Dose Therapy and Autologous Hematopoietic Cell Transplantation

Purpose

Platelets are blood cells that help the body to form clots to stop bleeding. Chemotherapy and autologous hematopoietic cell transplantation (healthy blood stem cells from a patient’s own body used to replace diseased or damaged bone marrow) can lower platelet counts, requiring patients to receive platelet transfusions.

Romiplostim is a medication designed to increase platelet production. In this study, researchers are assessing romiplostim to see if it can improve the recovery of platelet counts in patients receiving chemotherapy for an autologous stem cell transplant for a blood cancer and reduce the need for platelet transfusions.

The U.S. Food and Drug Administration has approved romiplostim to treat low platelet counts in people with a disorder called chronic immune thrombocytopenia; its use in this study is considered investigational. Romiplostim is given as an injection into the skin.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be receiving chemotherapy and autologous stem cell transplantation for multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Gerald Soff at 646-608-3724.

Protocol

20-180

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators